Business
Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 As a Potential Treatment for Duchenne Muscular Dystrophy
Toronto, Ontario--(Newsfile Corp. - March 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTC...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 As a Potential Treatment for Duchenne Muscular DystrophyToronto, Ontario--(Newsfile Corp. - March 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (\"Satellos\" or the \"Company\"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce additional results from further preclinical studies using the Company's lead drug candidate SAT-3153. The Company has designed SAT-3153 to be a selective inhibitor of a protein kinase (code named \"K9\") which it identified as a potential drug target to modulate polarity in muscle stem cells. On January 3, 2023, the Company indicated that results from preclinical ADME, PK and in vivo studies led to designation of SAT-3153 as its lead pre-IND drug development candidate (\"DC\") for the treatment of Duchenne muscular dystrophy (\"Duchenne\"). In a subsequent study with SAT-3153, in an acute injury model intended to determine if drug is acting rapidly on mechanism, Mdx mice treated with SAT-3153 displayed a statistically significant effect on polarity through new progenitor muscle cell formation vs placebo controls (n=5 per group), after one (1) week. In a further in vivo study, Mdx mice treated with SAT-3153 four times per week vs placebo controls (n=8 per group) showed a 19% increase in muscle force after two weeks. Additional preclinical studies have shown SAT-3153 to have no binding of the hERG channel (a key requirement to rule out possible cardiac toxicity), a plasma protein binding level of < 90% (indicating significant levels of free drug are available to initiate a therapeutic effect), and oral bioavailability. \"We see these results as a positive indication that SAT-3153 is on mechanism, affects skeletal muscle regeneration as intended, and has the potential to be safe on critical drug development criteria,\" said Frank Gleeson, President and CEO of Satellos. \"As preliminary, fact-finding studies which were designed to contribute to the profile of SAT-3153 as a DC and establish early efficacy benchmarks to guide further development studies, we are very pleased with these outcomes.\"Commented Dr. Michael Rudnicki, the Company's co-founder and Chief Scientific Office...